{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:14:40Z","timestamp":1784139280732,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Spinal Cord"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41393-022-00766-1","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T18:02:58Z","timestamp":1645120978000},"page":"716-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Urodynamic effect of vibegron on neurogenic lower urinary tract dysfunction in individuals with spinal cord injury: A retrospective study"],"prefix":"10.1038","volume":"60","author":[{"given":"Kyohei","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Teruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2553-8144","authenticated-orcid":false,"given":"Osamu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"766_CR1","unstructured":"Blok B, Castro-Diaz D, Del Popolo G, Groen J, Hamid R, Karsenty G, et al. Guidelines Associates: Ecclestone H, Musco S, Padilla-Fern\u00e1ndez B, Sartori A,\u2019t Hoen LA. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020 (Published online 2020)."},{"key":"766_CR2","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.juro.2018.01.046","volume":"199","author":"M Bywater","year":"2018","unstructured":"Bywater M, Tornic J, Mehnert U, Kessler TM. Detrusor acontractility after acute spinal cord injury\u2014myth or reality? J Urol. 2018;199:1565\u201370.","journal-title":"J Urol"},{"key":"766_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sc.2016.168","volume":"55","author":"H Sugiyama","year":"2017","unstructured":"Sugiyama H, Uemura O, Mori T, Okisio N, Unai K, Liu M, et al. Effect of imidafenacin on the urodynamic parameters of patients with indwelling bladder catheters due to spinal cord injury. Spinal Cord. 2017;55:187\u201391.","journal-title":"Spinal Cord"},{"key":"766_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pmr.2007.03.005","volume":"18","author":"G Samson","year":"2007","unstructured":"Samson G, Cardenas DD. Neurogenic bladder in spinal cord injury. Phys Med Rehabil Clin N. Am. 2007;18:255\u201374.","journal-title":"Phys Med Rehabil Clin N. Am"},{"key":"766_CR5","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00345-018-2367-7","volume":"36","author":"B Welk","year":"2018","unstructured":"Welk B, Schneider MP, Thavaseelan J, Traini LR, Curt A, Kessler TM, et al. Early urological care of patients with spinal cord injury. World J Urol. 2018;36:1537\u201344.","journal-title":"World J Urol"},{"key":"766_CR6","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00345-018-2388-2","volume":"36","author":"JT Stoffel","year":"2018","unstructured":"Stoffel JT, Van der Aa F, Wittmann D, Yande S, Elliott S. Neurogenic bowel management for the adult spinal cord injury patient. World J Urol. 2018;36:1587\u201392.","journal-title":"World J Urol"},{"key":"766_CR7","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/nau.23566","volume":"37","author":"J Krhut","year":"2018","unstructured":"Krhut J, Borovi\u010dka V, B\u00edlkov\u00e1 K, S\u00fdkora R, M\u00edka D, Mokri\u0161 J, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37:2226\u201333.","journal-title":"Neurourol Urodyn"},{"key":"766_CR8","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1002\/nau.23774","volume":"37","author":"B Welk","year":"2018","unstructured":"Welk B, Hickling D, McKibbon M, Radomski S, Ethans K. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2018;37:2810\u20137.","journal-title":"Neurourol Urodyn"},{"key":"766_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/nau.24604","volume":"40","author":"P Vasudeva","year":"2021","unstructured":"Vasudeva P, Prasad V, Yadav S, Kumar N, Saurav K, Prashanth YM, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity resulting from traumatic spinal cord injury: A prospective study. Neurourol Urodyn. 2021;40:666\u201371.","journal-title":"Neurourol Urodyn"},{"key":"766_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.4140\/TCP.n.2014.823","volume":"29","author":"R Bragg","year":"2014","unstructured":"Bragg R, Hebel D, Vouri SM, Pitlick JM. Mirabegron: A beta-3 agonist for overactive bladder. Consult Pharm. 2014;29:823\u201337.","journal-title":"Consult Pharm"},{"key":"766_CR11","doi-asserted-by":"publisher","first-page":"e13241","DOI":"10.1111\/and.13241","volume":"51","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Chiba K, Okada K, Fujisawa M. Effect of mirabegron on tight junction molecules in primary cultured rat Sertoli cells. Andrologia 2019;51:e13241.","journal-title":"Andrologia"},{"key":"766_CR12","unstructured":"Astellas Pharma Inc. Astellas Pharma Inc.: Approval for Betanis tablet, a treatment for OAB, in Japan. https:\/\/www.astellas.com\/system\/files\/news\/2018-06\/110701_2_Eg.pdf (accessed Jan 7, 2021)."},{"key":"766_CR13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","volume":"73","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for the treatment of patients with overactive bladder: A randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018;73:783\u201390.","journal-title":"Eur Urol"},{"key":"766_CR14","unstructured":"WO2018224989A1 - Use of vibegron to treat overactive bladder - Google Patents. https:\/\/patents.google.com\/patent\/WO2018224989A1\/en (accessed July 1, 2020)."},{"key":"766_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.106.115840","volume":"321","author":"T Takasu","year":"2007","unstructured":"Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2- phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective \u03b23-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321:642\u20137.","journal-title":"J Pharmacol Exp Ther."},{"key":"766_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","volume":"59","author":"SD Edmondson","year":"2016","unstructured":"Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, et al. Discovery of vibegron: A potent and selective \u03b23 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59:609\u201323.","journal-title":"J Med Chem"},{"key":"766_CR17","doi-asserted-by":"publisher","first-page":"172727","DOI":"10.1016\/j.ejphar.2019.172727","volume":"864","author":"T Yamazaki","year":"2019","unstructured":"Yamazaki T, Maruyama I. Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats. Eur J Pharm. 2019;864:172727.","journal-title":"Eur J Pharm"},{"key":"766_CR18","doi-asserted-by":"publisher","first-page":"173096","DOI":"10.1016\/j.ejphar.2020.173096","volume":"878","author":"I Maruyama","year":"2020","unstructured":"Maruyama I, Yamamoto S, Tsuchioka K, Yamazaki T. Effects of vibegron, a novel \u03b23-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction. Eur J Pharm. 2020;878:173096.","journal-title":"Eur J Pharm"},{"key":"766_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/nau.10066","volume":"21","author":"W Sch\u00e4fer","year":"2002","unstructured":"Sch\u00e4fer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, et al. Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn. 2002;21:261\u201374.","journal-title":"Neurourol Urodyn"},{"key":"766_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1179\/204577211X13207446293695","volume":"34","author":"SC Kirshblum","year":"2011","unstructured":"Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, et al. International standards for neurological classification of spinal cord injury (revised 2011). J Spinal Cord Med. 2011;34:535\u201346.","journal-title":"J Spinal Cord Med"},{"key":"766_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/iju.14186","volume":"27","author":"N Sekido","year":"2020","unstructured":"Sekido N, Igawa Y, Kakizaki H, Kitta T, Sengoku A, Takahashi S, et al. Clinical guidelines for the diagnosis and treatment of lower urinary tract dysfunction in patients with spinal cord injury. Int J Urol. 2020;27:276\u201388.","journal-title":"Int J Urol"},{"key":"766_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37\u201349.","journal-title":"Urology"},{"key":"766_CR23","doi-asserted-by":"publisher","first-page":"O209","DOI":"10.1111\/luts.12247","volume":"11","author":"T Maki","year":"2019","unstructured":"Maki T, Kajioka S, Itsumi M, Kareman E, Lee K, Shiota M, et al. Mirabegron induces relaxant effects via cAMP signaling\u2010dependent and \u2010independent pathways in detrusor smooth muscle. LUTS Low Urin Trac Symptoms. 2019;11:O209\u2013O217.","journal-title":"LUTS Low Urin Trac Symptoms"},{"key":"766_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pharmthera.2016.01.007","volume":"159","author":"MC Michel","year":"2016","unstructured":"Michel MC, Korstanje C. \u03b23-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. Pharm Ther. 2016;159:66\u201382.","journal-title":"Pharm Ther"},{"key":"766_CR25","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","volume":"62","author":"N Aizawa","year":"2012","unstructured":"Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel \u03b23-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62:1165\u201373.","journal-title":"Eur Urol"},{"key":"766_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/bph.14921","volume":"177","author":"I Silva","year":"2020","unstructured":"Silva I, Magalh\u00e3es\u2010Cardoso MT, Ferreirinha F, Moreira S, Costa AF, Silva D, et al. 3 Adrenoceptor\u2010induced cholinergic inhibition in human and rat urinary bladders involves the exchange protein directly activated by cyclic AMP 1 favoring adenosine release. Br J Pharm. 2020;177:1589\u2013608.","journal-title":"Br J Pharm"},{"key":"766_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.116.237313","volume":"360","author":"J Di Salvo","year":"2017","unstructured":"Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, et al. Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: Evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharm Exp Ther. 2017;360:346\u201355.","journal-title":"J Pharm Exp Ther"},{"key":"766_CR28","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/iju.14630","volume":"28","author":"N Shimizu","year":"2021","unstructured":"Shimizu N, Gotoh D, Nishimoto M, Hashimoto M, Saito T, Fujita K, et al. Efficacy of vibegron, A novel \u03b23-adrenoreceptor agonist, for lower urinary tract dysfunction in mice with spinal cord injury. Int J Urol. 2021;28:1068\u201372.","journal-title":"Int J Urol"},{"key":"766_CR29","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/nau.24486","volume":"39","author":"D Gotoh","year":"2020","unstructured":"Gotoh D, Shimizu N, Wada N, Kadekawa K, Saito T, Mizoguchi S, et al. Effects of a new \u03b23-adrenoceptor agonist, vibegron, on neurogenic bladder dysfunction and remodeling in mice with spinal cord injury. Neurourol Urodyn. 2020;39:2120\u20137.","journal-title":"Neurourol Urodyn"},{"key":"766_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/sc.2012.164","volume":"51","author":"J Krebs","year":"2013","unstructured":"Krebs J, Pannek J. Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion. Spinal Cord. 2013;51:306\u20139.","journal-title":"Spinal Cord"}],"container-title":["Spinal Cord"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41393-022-00766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41393-022-00766-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41393-022-00766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T14:05:01Z","timestamp":1661177101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41393-022-00766-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1038\/s41393-022-00766-1","relation":{},"ISSN":["1362-4393","1476-5624"],"issn-type":[{"value":"1362-4393","type":"print"},{"value":"1476-5624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"5 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the institutional review board of Murayama Medical Center (project approval number 20-3).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}